Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NR20
UPID:
DYRK4_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NR20; A8K8F7; Q8NEF2; Q92631
Background:
Dual specificity tyrosine-phosphorylation-regulated kinase 4 plays a pivotal role in cellular processes, with a possible non-essential role in spermiogenesis. This protein, encoded by the gene symbolized as Q9NR20, is crucial for the regulation of various signaling pathways.
Therapeutic significance:
Understanding the role of Dual specificity tyrosine-phosphorylation-regulated kinase 4 could open doors to potential therapeutic strategies. Its involvement in spermiogenesis suggests a potential impact on fertility treatments and reproductive health research.